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ril 16, 2013.his study sought to test the hypothesis that right bundle branch block (RBBB) patients have larger scar size than
left bundle branch block (LBBB) patients do.Background A proximal septal perforating branch of the left anterior descending (LAD) coronary artery most commonly perfuses
the right bundle branch and left anterior fascicle, but not the left posterior fascicle. Thus, proximal LAD occlusions
should cause RBBB, not LBBB.Methods We performed electrocardiograms and magnetic resonance imaging for scar quantiﬁcation in 233 patients with left
ventricular (LV) ejection fraction 35% who were receiving primary prevention implantable cardioverter-deﬁbrillators
(ICD cohort). Scar size and location were compared among patients with RBBB, LBBB, nonspeciﬁc LV conduction
delay, and QRS <120 ms. A second cohort of 20 hypertrophic cardiomyopathy patients undergoing alcohol septal
ablation was studied to determine whether controlled infarction in a proximal LAD septal perforator caused RBBB or
LBBB.Results In the ICD cohort, LV ejection fraction was similar between RBBB and LBBB patients (24.9% vs. 25.0%; p ¼ 0.98);
however, RBBB patients had signiﬁcantly larger scar size (24.0% vs. 6.5%; p < 0.0001). Patients with nonspeciﬁc LV
conduction delay or QRS <120 ms had intermediate scar size (12.9% and 14.4%, respectively). Those with RBBB
(compared with LBBB) were more likely to have ischemic heart disease (79% vs. 29%; p < 0.0001). In the alcohol
septal ablation cohort, 15 of 20 patients (75%) developed RBBB, but no patients developed LBBB.Conclusions In patients with LV ejection fraction 35%, RBBB is associated with signiﬁcantly larger scar size than LBBB is, and
occlusion of a proximal LAD septal perforator causes RBBB. In contrast, LBBB is most commonly caused by
nonischemic pathologies. (J Am Coll Cardiol 2013;62:959–67) ª 2013 by the American College of Cardiology
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960left bundle branch almost always
occurs at its junction with the
main bundle, often with histo-
logical ﬁndings of ﬁbrosis or
sclerosis with occasional calciﬁ-
cation (5–7). Furthermore, at this
location, the left bundle branch can
be compressed between connective
tissue of the central ﬁbrous body
and the base of the ventricular
septum (5–7), especially when
subjected to mechanical strain
fromahypertrophied or dilated left
ventricle (LV).
In chronic cardiomyopathy, pro-
longed QRS duration is associ-
ated with increased mortality (8);
however, the cause of the associ-
ation likely differs depending on
the conduction type. In LBBB,
the large delay between activation
of the interventricular septum
and LV free wall leads to dyssyn-
chronous and inefﬁcient LVcontraction (9). In RBBB, activation of the LV is normal;
however, increased mortality may be due to the association
of RBBB and large anteroseptal MI that portend poor
prognosis.
Cardiac magnetic resonance (CMR) with late gadoli-
nium enhancement (LGE) is the gold standard for
identifying the location of and quantifying the amount of
myocardial scar caused by prior MI or nonischemic
causes of cardiomyopathy (10). In a cohort of chronic
ischemic and nonischemic cardiomyopathy patients, we
used CMR to test the hypothesis that RBBB patients
have a larger scar burden than LBBB patients do because
RBBB patients have a higher prevalence of proximal
LAD MI and less frequent nonischemic pathologies. As
a proof-of-concept group, we also studied the ECG
characteristics of a cohort of patients with the obstructive
form of hypertrophic cardiomyopathy who underwent
percutaneous alcohol septal ablation of the proximal
septal perforator and could thus serve as a controlled
model of proximal anteroseptal infarction.
Methods
ICD cohort population. Patients referred clinically to
Johns Hopkins Medical Institutions for implantable
cardioverter-deﬁbrillator (ICD) placement for primary
prevention of sudden cardiac death were prospectively
enrolled between November 2003 and December 2010
(11). The population has been described previously
(11–14). All patients had to have LV ejection frac-
tion 35%, coronary angiography, no other indications for
ICD placement, and no contraindications to CMR.Patients were classiﬁed as “nonischemic” if they had no
history of MI or revascularization and no evidence of
coronary artery stenoses >50% of 2 or more epicardial
vessels or left main or proximal LAD stenosis >50%.
Other patients were classiﬁed as “ischemic.” All MI had
occurred >1 month prior to enrollment. This study
protocol was approved by the Johns Hopkins Institutional
Review Board. All patients gave written informed consent.
Hypertrophic cardiomyopathy alcohol septal ablation
cohort. Patients with hypertrophic cardiomyopathy referred
clinically to Johns Hopkins Medical Institutions for percu-
taneous alcohol septal ablation were enrolled between
December 2000 and November 2005 as part of a single-
center prospective cohort of CMR before and after septal
ablation. This study protocol was approved by the Johns
Hopkins Institutional Review Board. All patients gave
written informed consent.
CMR acquisition and analysis in ICD cohort. Patients
underwent cine and CMR-LGE imaging using a 1.5-T
scanner (GE Signa CV/I, GE Medical Systems, Milwau-
kee, Wisconsin; or Siemens Avanto, Siemens Medical
Solutions. Malvern, Pennsylvania). Image analysis was per-
formed using custom research software CINEtool (GE
Healthcare, Milwaukee, Wisconsin). Cine images were used
to measure ejection fraction and volumes, and LGE images
were used to measure total scar size for the entire LV. The
LGE area was outlined, and pixels with signal intensity
>50% of the maximum within the LGE area were labeled as
scar “core” (12,14). A region of normal myocardium without
artifacts was then selected and the peak signal intensity within
the normal myocardium was determined. Myocardium with
signal intensity greater than peak remote signal intensity
but <50% of maximal signal intensity within the LGE region
was labeled the “gray” zone to represent the heterogeneous
peri-scar zone (12,14). Total scar size was expressed as
core þ1/2 gray zone as a percentage of total LV mass (14).
Scar location was determined using the American Heart
Association’s 17-segment model of the LV (15). Patients
with ischemic cardiomyopathy were grouped into those
having infarct with a(n) LAD, right coronary artery (RCA),
and/or left circumﬂex infarction pattern (15). Patients with
nonischemic cardiomyopathy were grouped into 6 patterns:
1) no scar present; 2) scar conﬁned to the mid-wall
myocardium; 3) scar conﬁned to the epicardium; 4) scar
conﬁned to the endocardium; 5) transmural scar; and 6) scar
at the right ventricular insertion points based on previously
described patterns (16). Scar transmural involvement in each
of the 17 segments was graded on a 0-to-4-point scale as
described previously: 0 for 0% hyperenhancement; 1 for 1%
to 25% hyperenhancement; 2 for 26% to 50% hyper-
enhancement; 3 for 51% to 75% hyperenhancement; and 4
for 76% to 100% hyperenhancement (17).
ECG analysis for both cohorts. ECG at the time of CMR
were analyzed according to previously speciﬁed criteria
(14,18,19):
Table 1 Baseline Characteristics of ICD Cohort
RBBB
(n ¼ 19)
LBBB
(n ¼ 45)
LVCD
(n ¼ 35)
QRSd <120 ms
(n ¼ 134)
p Value
RBBB vs. LBBB
Age, yrs 59.1  7.8 59.7  11.4 64.2  12.6 54.6  12.2 0.85
Female 14 (74) 29 (64) 27 (77) 109 (81) 0.48
LVEF, % 24.9  8.7 25.0  9.0 26.1  8.9 28.3  8.9 0.98
Ischemic 15 (79) 13 (29) 25 (71) 78 (58) <0.0001*
QRS duration, ms 150.3  16.8 162.2  20.3 130.7  14.1 98.3  10.7 0.028*
Ethnicity 0.27
Caucasian 15 (79) 34 (76) 27 (77) 86 (64)
African American 3 (16) 10 (22) 8 (23) 42 (31)
Other 1 (5) 0 (0) 0 (0) 5 (4)
NYHA functional class 0.095*
I 4 (21) 2 (4) 9 (26) 43 (32)
II 7 (37) 16 (36) 4 (11) 68 (51)
III 8 (42) 27 (60) 22 (63) 23 (17)
LVEDV/BSA, ml/m2 114.9  34.4 137.2  50.0 131.4  43.1 115.6  36.3 0.081*
LVESV/BSA, ml/m2 89.0  37.3 105.9  51.7 98.8  40.5 84.8  34.6 0.20*
LV mass/BSA, ml/m2 73.5  22.5 82.1  32.6 78.9  27.0 70.2  20.8 0.30*
Values are mean  SD or n (%). Bold values are statistically signiﬁcant. *p < 0.05 for groupwise comparison among 4 groups.
BSA ¼ body surface area; ICD ¼ implantable cardioverter-deﬁbrillator; LBBB ¼ left bundle branch block; LV ¼ left ventricle/ventricular; LVCD ¼ left
ventricular conduction delay; LVEDV ¼ left ventricular end-diastolic volume; LVEF ¼ left ventricular ejection fraction; LVESV ¼ left ventricular end-
systolic volume; NYHA ¼ New York Heart Association; RBBB ¼ right bundle branch block; QRSd ¼ QRS duration.
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961 LBBB: QRS duration 140 ms (men) or 130 ms
(women), QS or rS complex in leads V1 and V2 with
mid-QRS notching/slurring in 2 of the leads I, aVL,
V1, V2, V5, or V6;
 RBBB: QRS duration 120 ms with rR’ or qR
complex in lead V1 and a wide S wave in lead I
(patients with left axis deviation [180 to 45] were
classiﬁed as left anterior fascicular block þ RBBB;
 Nonspeciﬁc LV conduction delay (LVCD): QRS
duration 120 ms and QS or rS complex in lead V1,
but not meeting LBBB or RBBB criteria; and
 QRS duration <120 ms.
Statistical analysis. Variables following Gaussian distribu-
tions were compared by ECG conduction type with parame-
tric measures (2-sample Student t test, 1-way analysis of
variance), whereas those not following Gaussian distributions
were analyzed nonparametrically (Wilcoxon rank sum,
nonparametric 1-way analysis of variance). Categorical vari-
ables were evaluated by chi-square. Analysis was performed
separately comparing RBBB and LBBB patients and
comparing all 4 ECG conduction types. The p values <0.05
were considered signiﬁcant.Results
Of the 235 primary prevention ICD patients available for
analysis, 2 were excluded because only ventricular-paced
ECG were available. The remaining 233 (77% were men)
had a mean age of 57 years, a mean LV ejection fraction of
27%, 56% ischemic etiology, and a distribution of New York
Heart Association heart failure classes of 25% class I, 41%
class II, and 34% class III. There were no differences in age,sex, ethnicity, heart failure class, or LV ejection fraction
between RBBB and LBBB patients (Table 1). However,
there were signiﬁcant differences in scar size, anatomic scar
location, and prevalence of ischemic versus nonischemic
cardiomyopathy. In addition, there was a trend toward larger
LV end-diastolic volume in LBBB patients.
Right versus left bundle branch block. Figure 1 shows the
CMR-LGE image of a RBBB patient with ischemic
cardiomyopathy and a large anteroseptal scar involving 45%
of the LV, and Figure 2 shows the CMR-LGE of a LBBB
patient with nonischemic cardiomyopathy and no scar. As
a group, the mean scar size in RBBB patients was signi-
ﬁcantly greater than in LBBB patients (24.0% vs. 6.5%;
p < 0.0001), whereas patients with nonspeciﬁc LVCD or
QRS duration <120 ms had intermediate scar size (12.9%
and 14.4%, respectively) (Table 2). Of note, even though
analysis in this study was performed with the pre-speciﬁed
strict LBBB criteria (14,18,20), deﬁning LBBB with
conventional LBBB criteria (QRS 120 ms, with QS wave
or rS complex in lead V1) still resulted in a large difference
in scar size between LBBB (9.3  10.2% LV) and RBBB
(24.0  15.7% LV) patients (p < 0.0001).
The difference in scar size was partially explained by
a higher prevalence of ischemic cardiomyopathy in RBBB
compared with LBBB patients (79% vs. 29%; p < 0.0001).
However, among ischemic cardiomyopathy patients, a larger
scar size persisted among those with RBBB versus those
with LBBB (28.5% vs. 14.7%; p ¼ 0.006). The scar
distribution in each of the 17 segments is shown in polar
plots in Figure 3. The right bundle branch runs approxi-
mately through segment 8 (mid-anteroseptal wall), which
was the segment with the highest transmural scar grade
among the RBBB patients, and was signiﬁcantly higher than
Figure 1 CMR-LGE and ECG of RBBB Patient With Ischemic Cardiomyopathy and Large Anteroseptal Scar
This patient had extensive scarring (arrows) by cardiac magnetic resonance late gadolinium enhancement (CMR-LGE) (A) from a prior proximal left anterior descending coronary
artery occlusion. The patient’s electrocardiogram (ECG) (B) showed a right bundle branch block (RBBB) with left anterior fascicular block.
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962the mid-anteroseptal scar grade (measure of scar transmural
involvement) in LBBB patients (2.47 vs. 0.89; p ¼ 0.001).
When considering only ischemic patients, 11 of 15 (73%)
RBBB patients had scar consistent with LAD occlusions
(2 of whom also had scar in a second territory), and the
average scar size was 34.8% of the LV (range 19% to 50%
LV) for LAD-only scar. Of the 4 other ischemic RBBB
patients, 2 were RCA-territory scars, 1 was a left circumﬂex
scar, and 1 was not a typical ischemic pattern (scar near right
ventricular insertion points). In contrast, among the 13
ischemic LBBB patients, there were 3 with scar patterns
consistent with LAD þ RCA, 6 LAD-only, 2 RCA-only,
and 2 left circumﬂex-only. Prior necropsy studies have
suggested that both LAD and RCA infarcts would usually
be required for MI to be the sole cause of a LBBB, and it is
unlikely for a LAD-only MI to cause a LBBB. Among the 6
LAD-only LBBB patients, only 1 of them had a large scar
(35% LV), whereas the remainder had scar sizes not more
than 16% of the LV (range: 5% to 16%). This suggests thatin at least 5 of these 6 cases, the LAD scar was not likely the
direct cause of the LBBB, but rather the LBBB developed
due to stress and strain on the left bundle ﬁbers associated
with LV dilation and progressive cardiomyopathy. Indeed,
there was a trend toward larger LV end-diastolic volume
(corrected for body surface area) in LBBB versus RBBB
patients overall (137.2 vs. 114.9 ml/m2; p ¼ 0.081).
Among nonischemic patients, 0 of 4 RBBB patients had
no scar, whereas 20 of 32 (63%) LBBB patients had no scar
(p ¼ 0.017 for comparison). There was no signiﬁcant
difference in the scar patterns (mid-wall, epicardial, endo-
cardial, transmural vs. right ventricular insertion) in RBBB
versus LBBB patients.
Alcohol septal ablation. QRS duration was normal in all
hypertrophic cardiomyopathy patients prior to the septal
ablation. Subsequent to the alcohol septal ablation of
a proximal LAD septal perforator, 15 of 20 (75%) developed
RBBB, whereas no patients developed LBBB. Figure 4
shows the ECG of a patient before and after alcohol
Figure 2 CMR-LGE and ECG of LBBB Patient
This patient had nonischemic cardiomyopathy and no scar present by cardiac magnetic resonance late gadolinium enhancement (CMR-LGE) (A). The patient’s ECG (B) showed
left bundle branch block (LBBB). Abbreviations as in Figure 1.
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963septal ablation that developed RBBB. The patients’ CMR-
LGE image shows a focal area of LGE in the basal
septum representing the area of necrosis causing RBBB.
Among those who developed RBBB, 3 of 15 also devel-
oped left anterior fascicular block. QRS duration increased
by 42  11 ms among those developing RBBB (p < 0.0001
compared with baseline), whereas there was no signiﬁcant
change in QRS duration among those that did not develop
RBBB (p ¼ 0.24). No patients developed left anterior
fascicular block without RBBB.
Discussion
Our study supports the premise that RBBB has a strong
association with large anteroseptal scar in cardiomyopathy
patients, and occlusion of a proximal LAD septal perforator
causesRBBB. In contrast, themajority of LBBBpatients havenonischemic cardiomyopathies and, even among those with
ischemic cardiomyopathy, LBBB patients have signiﬁcantly
lower overall scar burden than RBBB patients do, whereas
LVCD and QRS duration <120 ms patients have interme-
diate scar sizes. These results oppose the conventional clinical
concept that LBBB is caused by massive septal infarction.
Instead, LBBB is more likely caused by a combination of
sclerosis and ﬁbrosis combined with mechanical strain on the
left bundle ﬁbers near the left bundle junction with the main
bundle, where the conduction ﬁbers are sandwiched between
the connective tissue of the central ﬁbrous body and the base of
the ventricular septum (5–7).However, it is possible that these
observations are an artifact of survival bias. The relationship
between proximal LAD occlusions and RBBB (but not
LBBB) was further conﬁrmed by our cohort with hypertro-
phic cardiomyopathy in whom alcohol ablation of a proximal
LAD septal perforator led to RBBB in 75% of patients, but
Table 2 CMR-LGE Scar Size of ICD Cohort
RBBB LBBB LVCD QRSd <120 ms
p Value
RBBB vs. LBBB
All 19 45 35 134
Scar size, %LV 24.0  15.1 6.5  9.4 12.9  10.0 14.4  13.7 <0.0001*
Scar core, %LV 17.8  11.1 4.3  6.1 9.4  7.1 10.6  10.4 <0.0001*
Scar gray, %LV 12.3  9.2 4.2  7.0 7.0  6.4 7.6  7.9 <0.0001*
Ischemic 15 13 25 77
Scar size, %LV 28.5  13.7 14.7  9.7 17.4  8.2 22.5  11.0 0.006*
Scar core, %LV 21.0  10.2 10.0  6.2 12.6  5.7 16.7  8.8 0.002*
Scar gray, %LV 14.7  8.6 9.0  7.3 9.5  6.0 11.6  7.1 0.072
Nonischemic 4 32 10 57
Scar size, %LV 7.3  4.7 3.2  7.1 1.8  1.9 3.4  8.1 0.27
Scar core, %LV 5.7  3.4 2.0  4.3 1.4  1.6 2.3  5.4 0.110
Scar gray, %LV 3.1  4.5 2.3  6.0 0.8  0.8 2.2  5.4 0.80
Values are n or mean  SD. Bold values are statistically signiﬁcant. *p < 0.05 for groupwise comparison among 4 groups.
CMR-LGE ¼ cardiac magnetic resonance late gadolinium enhancement; %LV ¼ percentage of left ventricle; other abbreviations as in Table 1.
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964not to LBBB. This evidence that LAD occlusions cause
RBBB, but not LBBB, has important potential clinical
implications for primary prevention ICD and cardiac
resynchronization therapy (CRT) patients, such as those in
this study, but also potentially for acute MI patients.Figure 3 Segmental Scar Distribution in the ICD Cohort
Polar plots show the average transmural scar extent within each of the 17 American Hea
hyperenhancement; 1 for 1% to 25% hyperenhancement; 2 for 26% to 50% hyperenhanc
hyperenhancement) (17). The ﬁgure is scaled from no scar (light yellow) to a transmura
segment 8 (mid-anteroseptal), which had the highest scar grade of any segment in RBBB
conduction delay; QRSd ¼ QRS duration; other abbreviations as in Figures 1 and 2.CRT studies performed in the past decade were limited
by the lack of distinction between ventricular block types.
CRT trials enrolled patients with QRS duration 120 ms
(without distinction between conduction types) and showed
that CRT reduced heart failure symptoms, heart failurert Association–deﬁned myocardial segments graded on a 0-to-4-point scale (0 for 0%
ement; 3 for 51% to 75% hyperenhancement; and 4 for 76% to 100%
l scar grade of 2.5 (dark red). Note that the right bundle branch runs through
patients. ICD ¼ implantable cardioverter-deﬁbrillator; LVCD ¼ left ventricular
Figure 4 ECG and CMR-LGE of Patient Developing RBBB After Alcohol Septal Ablation
This hypertrophic cardiomyopathy patient had a baseline ECG (A) showing left ventricular hypertrophy, but not bundle branch block. Alcohol septal ablation was performed in
a proximal left anterior descending coronary artery septal perforator leading to necrosis highlighted by arrows in the CMR-LGE image (B). Post-septal ablation ECG (C) showed
that RBBB developed. Abbreviations as in Figure 1.
JACC Vol. 62, No. 11, 2013 Strauss et al.
September 10, 2013:959–67 RBBB (Not LBBB) and Large Anteroseptal Scar
965
Strauss et al. JACC Vol. 62, No. 11, 2013
RBBB (Not LBBB) and Large Anteroseptal Scar September 10, 2013:959–67
966hospitalization, and mortality (21–26). However, more
recent analysis has suggested that the beneﬁt from CRT is
driven by LBBB patients (26–28), especially in the
MADIT-CRT (Multicenter Automated Deﬁbrillator
Implantation Trial) that enrolled New York Heart Associ-
ation class I and II patients (27). In that trial, neither RBBB
patients nor nonspeciﬁc LVCD patients beneﬁted from
CRT. Furthermore, large outcome studies of Medicare
patients demonstrated that, among CRT recipients,
mortality is highest with RBBB, intermediate with LVCD,
and lowest with LBBB (29,30). CRT likely beneﬁts LBBB
patients most because RBBB and LVCD patients have
normal Purkinje activation of the LV, but poor prognosis
with RBBB may also be due to RBBB association with large
scar burden, as demonstrated in the present study.
Our results have potential implications for acute MI
patients, as well. Prior studies have described the association
between new onset LBBB and occlusion of the proximal
LAD artery and large MI size (2). However, this was based
on remote studies using Q waves in leads V1 to V3 to
determine anteroseptal MI location and creatine kinase–
measured infarct size (1). Recent studies using CMR-LGE
have demonstrated that in LBBB, large R waves (not Q
waves) in leads V1 to V3 represent anteroseptal MI (14,18).
As discussed previously, post-mortem studies support the
observation that proximal LAD septal perforators most
commonly perfuse the right bundle branch and the anterior
half of left bundle branch, whereas the RCA (via the
atrioventricular-nodal artery) most commonly perfuses the
posterior half of the left bundle branch (4). Thus, proximal
LAD occlusions can cause RBBB and/or left anterior
fascicular block; however, both proximal LAD and RCA
occlusions would typically be required for infarcts to be the
cause of LBBB. In addition, some patients diagnosed with
LBBB by conventional ECG criteria do not have activation
consistent with LBBB and the recently proposed strict
LBBB criteria (14,18,20) used in the present study should be
assessed in future studies in patients presenting with symp-
toms of acute coronary syndromes.
Our data from the hypertrophic cardiomyopathy patients
undergoing septal ablation of a proximal LAD septal
perforator support this concept as 15 of 20 patients developed
RBBB (with 3 developing left anterior fascicular block in
addition to RBBB), whereas no patients developed LBBB.
This is consistent with previous studies (31,32). Qin et al.
(31) reported that 62% of patients developed RBBB after
septal ablation, whereas 6% developed LBBB. It is possible
that the limited number of patients supposedly developing
LBBB did not actually develop LBBB, but rather left ante-
rior fascicular block that caused the patients to meet
conventional ECG criteria for LBBB, but they would not
have met strict criteria for LBBB used in this study (20).
Study limitations. All patients enrolled in the ICD cohort
portion of this study had an ejection fraction 35% and metcriteria for primary prevention ICD. Thus, the results cannot
necessarily be extrapolated outside of this population.
Although we comment on how our ﬁndings might translate
to patients presenting with bundle branch block and acute
MI, this should be interpreted with caution and requires
further study. Although the subgroup comparison of is-
chemic patients still demonstrates smaller scar in the LBBB
group, this may be an artifact of survival bias; speciﬁcally, that
patients with large anterior MI who develop or have LBBB
are less likely to survive long enough to qualify for an ICD.
Studying hypertrophic cardiomyopathy patients undergoing
alcohol septal ablation of a proximal LAD septal perforator
did allow us to investigate the direct effect of proximal LAD
occlusion in an acute setting; however, directed alcohol
infusion down a septal perforator may not be representa-
tive of naturally occurring LAD coronary occlusions.
Conclusions
In a chronic cardiomyopathy cohort, RBBB is associated
with ischemic cardiomyopathy and large anteroseptal scar,
whereas LBBB is associated with nonischemic etiologies.
The large myocardial scar in RBBB patients may explain
why they have even worse mortality than do nonspeciﬁc
LVCD patients receiving CRT. This study highlights that
the LAD branches perfuse the right bundle branch and left
anterior fascicle, but not the entire left bundle branch.
Future clinical prognostic studies should speciﬁcally distin-
guish between RBBB and LBBB patients rather than
consider them homogeneously. Assessment of scar burden as
another risk factor may also be of value.
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